Survivin-Targeted T-Cell Therapy Shows Durable Activity in Advanced Recurrent Ovarian Cancer
December 3rd 2020
December 3, 2020 — The survivin-targeted T-cell therapy DPX-Survivac, when used in combination with intermittent low-dose cyclophosphamide, prolonged clinical benefit with promising tolerability in patients with recurrent, advanced platinum-sensitive and -resistant ovarian cancer.